B Cell Lymphoma
News
Rituximab maintenance has a durable benefit in follicular lymphoma
At a median of 9 years of follow-up, progression-free survival was extended versus observation but there was no difference in overall survival.
News
CAR T-cell ‘cocktail’ may overcome antigen escape relapse
The pilot study used a sequential infusion of a third-generation chimeric antigen receptor T-cell “cocktail” targeting CD19 and CD22.
News
Adding polatuzumab extends survival in relapsed/refractory DLBCL
The combination offers a viable alternative for a group of patients with historically “dismal” outcomes, investigators said.
News
FDA approves Brukinsa for relapsed, refractory MCL
The Bruton tyrosine kinase (BTK) inhibitor zanubrutinib showed high overall response rates in two clinical trials.
News
Gene signature may help guide initial CLL treatment choice
A 17-gene expression signature may help predict which patients with IGHV-unmutated disease will benefit from frontline FCR chemoimmunotherapy or...
Conference Coverage
Armored CAR T cells elicit responses in NHL patients
NATIONAL HARBOR, MD. – ICTCAR014, a dominant negative PD-1 armored CAR T-cell therapy, produced responses in 12 of 13 non-Hodgkin lymphoma...
Conference Coverage
Consider renal function in TLS risk assessment of venetoclax-treated CLL
EDINBURGH – Impaired renal function may indicate excess risk of tumor lysis syndrome (TLS) in venetoclax-treated...
News
Pembrolizumab shows promise for relapsed/refractory PMBCL
The findings raise the question of whether PD-1 blockade could resensitize tumors to chemotherapy.
Opinion
Primary CNS lymphoma: R-CHOP hits back
Twenty years after it was concluded that there was no role for R-CHOP in the treatment of primary CNS lymphoma, researchers are reconsidering that...
Conference Coverage
PJP prophylaxis may be unnecessary for CLL patients on BTK inhibitors
EDINBURGH – The findings show an overall low pneumocystis jiroveci pneumonia prevalence in patients not receiving prophylaxis.